[1] Babkin IV, Babkina IN, Tikunova NV. An update of orthopoxvirus molecular evolution. Viruses 2022;14(2):388. https://doi.org/10.3390/v14020388CrossRef
[2] Kumar N, Acharya A, Gendelman HE, Byrareddy SN. The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun 2022;131:102855. https://doi.org/10.1016/j.jaut.2022.102855CrossRef
[3] Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the democratic republic of Congo. J Infect Dis 2017;216(7):824 − 8. https://doi.org/10.1093/infdis/jix260CrossRef
[4] Lapa D, Carletti F, Mazzotta V, Matusali G, Pinnetti C, Meschi S, et al. Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding. Lancet Infect Dis 2022;22(9):1267 − 9. https://doi.org/10.1016/S1473-3099(22)00513-8CrossRef
[5] Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, et al. Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series. Lancet 2022;400(10367):1953 − 65. https://doi.org/10.1016/S0140-6736(22)02187-0CrossRef
[6] Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. Lancet Infect Dis 2022;22(12):e349 − 58. https://doi.org/10.1016/S1473-3099(22)00574-6CrossRef
[7] Li ET, Guo XP, Hong DX, Gong QZ, Xie WY, Li TT, et al. Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus. Signal Transduct Target Ther 2023;8(1):350. https://doi.org/10.1038/s41392-023-01574-6CrossRef
[8] Fine PEM, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol 1988;17(3):643 − 50. https://doi.org/10.1093/ije/17.3.643CrossRef
[9] Bertran M, Andrews N, Davison C, Dugbazah B, Boateng J, Lunt R, et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis 2023;23(7):828 − 35. https://doi.org/10.1016/S1473-3099(23)00057-9CrossRef
[10] Montero Morales L, Barbas Del buey JF, Alonso García M, Cenamor Largo N, Nieto Juliá A, Vázquez Torres MC, et al. Post-exposure vaccine effectiveness and contact management in the mpox outbreak, Madrid, Spain, May to August 2022. Euro Surveill 2023;28(24):2200883. https://doi.org/10.2807/1560-7917.ES.2023.28.24.2200883CrossRef
[11] Perdiguero B, Pérez P, Marcos-Villar L, Albericio G, Astorgano D, Álvarez E, et al. Highly attenuated poxvirus-based vaccines against emerging viral diseases. J Mol Biol 2023;435(15):168173. https://doi.org/10.1016/j.jmb.2023.168173CrossRef
[12] Esparza J, Lederman S, Nitsche A, Damaso CR. Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industry. Vaccine 2020;38(30):4773 − 9. https://doi.org/10.1016/j.vaccine.2020.05.037CrossRef
[13] Kretzschmar M, Wallinga J, Teunis P, Xing SQ, Mikolajczyk R. Correction: frequency of adverse events after vaccination with different vaccinia strains. PLoS Med 2006;3(10):e429. https://doi.org/10.1371/journal.pmed.0030272CrossRef
[14] Al-Musa A, Chou J, LaBere B. The resurgence of a neglected orthopoxvirus: Immunologic and clinical aspects of monkeypox virus infections over the past six decades. Clin Immunol 2022;243:109108. https://doi.org/10.1016/j.clim.2022.109108CrossRef
[15] Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults. Vaccine 2009;27(10):1637 − 44. https://doi.org/10.1016/j.vaccine.2008.11.079CrossRef
[16] van Nispen C, Reffett T, Long B, Gottlieb M, Frawley TC. Diagnosis and management of monkeypox: a review for the emergency clinician. Ann Emerg Med 2023;81(1):20 − 30. https://doi.org/10.1016/j.annemergmed.2022.07.014CrossRef
[17] Petersen BW, Harms TJ, Reynolds MG, Harrison LH. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses - recommendations of the advisory committee on immunization practices (ACIP) 2015. MMWR Morb Mortal Wkly Rep 2016;65(10):257 − 62. https://doi.org/10.15585/mmwr.mm6510a2CrossRef
[18] Paran N, Sutter G. Smallpox vaccines: new formulations and revised strategies for vaccination. Hum Vaccin 2009;5(12):824 − 31. https://doi.org/10.4161/hv.10295CrossRef
[19] Kennedy JS, Greenberg RN. IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009;8(1):13 − 24. https://doi.org/10.1586/14760584.8.1.13CrossRef
[20] Volz A, Sutter G. Modified vaccinia virus ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res 2017;97:187 − 243. https://doi.org/10.1016/bs.aivir.2016.07.001CrossRef
[21] Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D. Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox. N Engl J Med 2019;381(20):1897 − 908. https://doi.org/10.1056/NEJMoa1817307CrossRef
[22] Ryckeley C, Goodwin G, Alvarez-Calderon A. The reemerging condition of vaccinia: a case report and brief review of monkeypox and vaccinia vaccines. Am J Case Rep 2023;24:e941006. https://doi.org/10.12659/AJCR.941006CrossRef
[23] Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006;24(47-48):7009 − 22. https://doi.org/10.1016/j.vaccine.2006.03.087CrossRef
[24] Persad G, Leland RJ, Ottersen T, Richardson HS, Saenz C, Schaefer GO, et al. Fair domestic allocation of monkeypox virus countermeasures. Lancet Public Health 2023;8(5):e378 − 82. https://doi.org/10.1016/S2468-2667(23)00061-0CrossRef
[25] Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, et al. A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of modified vaccinia ankara smallpox vaccine (MVA-BN®) in 56-80-Year-old subjects. PLoS One 2016;11(6):e0157335. https://doi.org/10.1371/journal.pone.0157335CrossRef
[26] Sah R, Paul D, Mohanty A, Shah A, Mohanasundaram AS, Padhi BK. Monkeypox (Mpox) vaccines and their side effects: the other side of the coin. Int J Surg 2023;109(2):215 − 7. https://doi.org/10.1097/JS9.0000000000000142CrossRef
[27] Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 2013;207(12):1888 − 97. https://doi.org/10.1093/infdis/jit105CrossRef
[28] Overton ET, Lawrence SJ, Stapleton JT, Weidenthaler H, Schmidt D, Koenen B, et al. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine 2020;38(11):2600 − 7. https://doi.org/10.1016/j.vaccine.2020.01.058CrossRef
[29] Garde V, Harper D, Fairchok M. Tertiary contact vaccinia in a breastfeeding infant. JAMA 2004;291(6):725 − 7. https://doi.org/10.1001/jama.291.6.725CrossRef
[30] Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ, et al. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71(22):734 − 42. https://doi.org/10.15585/mmwr.mm7122e1CrossRef
[31] Yan K, Tang LK, Xiao FF, Zhang P, Lu CM, Hu LY, et al. Monkeypox and the perinatal period: what does maternal-fetal medicine need to know? World J Pediatr 2023;19(3):213-23. http://dx.doi.org/10.1007/s12519-022-00630-5.
[32] Wang Y, Yang KW, Zhou H. Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: a rapid review. Int J Biol Macromol 2023;245:125515. https://doi.org/10.1016/j.ijbiomac.2023.125515CrossRef
[33] Mucker EM, Golden JW, Hammerbeck CD, Kishimori JM, Royals M, Joselyn MD, et al. A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge. J Virol 2022;96(3):e0150421. https://doi.org/10.1128/JVI.01504-21CrossRef
[34] Golden JW, Josleyn MD, Hooper JW. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 2008;26(27-28):3507-15. https://www.sciencedirect.com/science/article/pii/S0264410X08004556.
[35] Fang ZH, Monteiro VS, Renauer PA, Shang XB, Suzuki K, Ling XY, et al. Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Res 2023;33(5):407 − 10. https://doi.org/10.1038/s41422-023-00792-5CrossRef
[36] Zhang NB, Cheng X, Zhu YL, Mo OY, Yu HQ, Zhu LQ, et al. Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity. Sci China Life Sci 2023;66(10):2329 − 41. https://doi.org/10.1007/s11427-023-2378-xCrossRef
[37] Xiao YH, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 2007;25(7):1214 − 24. https://doi.org/10.1016/j.vaccine.2006.10.009CrossRef
[38] Hou FJ, Zhang YT, Liu XH, Murad Y, Xu J, Yu ZB, et al. Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge. bioRxiv, 2022: p. 2022.11.19.517190. https://doi.org/10.1101/2022.11.19.517190.
[39] Xia H, He YR, Zhan XY, Zha GF. Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice. Antiviral Res 2023;216:105668. https://doi.org/10.1016/j.antiviral.2023.105668CrossRef
[40] National Medical Center for Infectious Diseases (Huashan Hospital, Fudan University), Infectious Disease Prevention and Control, Chinese Preventive Medicine Association. Mpox prevention guideline for the public (2023). Chin J Infect Dis 2023;41(10):623-30. https://rs.yiigle.com/cmaid/1464545. (In Chinese). 
[41] Zheng M, Du M, Yang GH, Yao YM, Qian XH, Zhi Y, et al. Mpox vaccination hesitancy and its associated factors among men who have sex with men in China: a national observational study. Vaccines 2023;11(9):1432. https://www.mdpi.com/2076-393X/11/9/1432.